By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

OncoGenex Pharmaceuticals Inc. 

1522 217th Place SE
Suite 100
Bothell  Washington  98021  U.S.A.
Phone: 425-686-1500 Fax: 425-686-1600


SEARCH JOBS

OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer. We have a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development.

We currently have five product candidates in development: OGX-011, OGX-427, SN2310, CSP-9222 and OGX-225. Three of the products are in clinical development.

We have conducted five phase 2 clinical trials to evaluate the ability of OGX-011 to enhance the effects of therapy in prostate, non-small cell lung and breast cancer.

In December 2009, we announced that we entered into a Collaboration and License Agreement with Teva Pharmaceutical Industries, for the development and global commercialization of OGX-011. In connection with the Collaboration Agreement, OncoGenex and Teva developed a Clinical Development Plan under which the following three phase 3 clinical trials will be initiated:

• a phase 3 clinical trial of OGX-011 in approximately 300 patients with second-line castrate resistant prostate cancer;
• a phase 3 clinical trial of OGX-011 in approximately 800 patients with first-line castrate resistant prostate cancer; and
• a phase 3 clinical trial of OGX-011 in at least 700 patients with first-line non-small cell lung cancer.

We have reached an agreement with the U.S. Food and Drug Administration (FDA) on the design of two Phase 3 registration trials of OGX-011 in patients with CRPC via the Special Protocol Assessment (SPA) process.

Learn more about OncoGenex at www.oncogenex.com

US Operations: Suite 100, 1522 217th Place SE, Bothell, WA 98021. Phone (425) 686-1500

Canadian Operations: Suite 400 – 1001 West Broadway, Vancouver, BC V6H 4B1. Tel: (604) 736-3678



Key Statistics


Email:
Ownership: Public

Web Site: OncoGenex Pharmaceuticals Inc.
Employees:
Symbol: OGXI
 









Company News
OncoGenex Pharmaceuticals Inc. (OGXI) To Report Second Quarter 2015 Financial Results On August 13, 2015 7/31/2015 11:29:02 AM
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Custirsen Phase 3 "ENSPIRIT Trial Continues Following Completion Of Final Futility Survival Analysis 7/13/2015 6:25:44 AM
FDA Agrees With OncoGenex Pharmaceuticals Inc. (OGXI)' Phase 3 AFFINITY Protocol Amendment 6/10/2015 6:41:18 AM
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Data From Borealis-1 Trial Showing Clinical Benefit With Apatorsen In Metastatic Bladder Cancer 6/1/2015 10:49:08 AM
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Data From The Phase 3 SYNERGY Trial Showing A Survival Benefit With Custirsen In Patients With Poor Prognosis 6/1/2015 6:10:10 AM
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Data To Be Presented At ASCO 2015 Annual Meeting 5/20/2015 10:53:17 AM
OncoGenex Pharmaceuticals Inc. (OGXI) Reports Financial Results For First Quarter 2015 5/14/2015 3:14:19 PM
OncoGenex Pharmaceuticals Inc. (OGXI) To Report First Quarter 2015 Financial Results On May 14, 2015 5/4/2015 2:09:51 PM
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Share Purchase Agreement With Lincoln Park Capital Fund, LLC 4/30/2015 6:46:43 AM
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Custirsen Phase 3 "ENSPIRIT Trial Update 4/30/2015 6:19:57 AM
12345678910...
//-->